Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications

NCT01406015 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Obesity
Insulin Resistance

Interventions

DRUG: Spironolactone
DRUG: Placebo

Sponsor

Brigham and Women's Hospital